
|Articles|November 1, 2009
Low-risk prostate cancer well managed with active surveillance
Drs. Scott B. Shappell and Leonard S. Marks discuss clinical use of urine PCA3 mRNA testing for prostate cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
3
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5











